Cynosure launches two new products to expand portfolio of aesthetic treatments

Hologic’s Cynosure division announced today the launch of two new products that expand the Company’s growing portfolio of innovative aesthetic treatments — the TempSure® Firm handpiece and a petite mask for SculpSure® submental treatments. SculpSure submental treatments are now cleared by the U.S. Food and Drug Administration (FDA) for patients with a body mass index (BMI) up to 49 — the highest BMI clearance on the market for submental treatments.

The TempSure Firm handpiece is the latest addition to the TempSure platform.  It delivers monopolar radiofrequency energy through unique massage heads to gently heat tissue and temporarily reduce the appearance of cellulite. The new 60 mm handpiece allows practitioners to treat larger areas of the body at a faster rate, without surgery or downtime.

Cynosure also received 510(k) clearance from the FDA for its petite submental mask, which attaches to the SculpSure platform. This new product will allow practitioners to perform WarmSculpting™ Profile treatments of submental fat (known as "double chin") on patients with a narrow jawline. The new submental mask makes the treatment accessible to an even broader audience. The FDA clearance also includes an expanded BMI range for all SculpSure submental treatments, now available to patients with a BMI up to 49 — the highest BMI clearance on the market for submental treatments.

The WarmSculpting Profile treatment was already a game changer for addressing the double chin, and after listening to customer feedback, we are excited to introduce the petite mask — the latest evolution of the cutting-edge SculpSure device. Our clinicians tell us almost 20 percent of their patients have smaller, narrow jawlines, and with the new petite mask, they can help even more men and women feel their best with non-surgical fat reduction in that area. The updated BMI clearance of 49 for all submental treatments is a clear competitive advantage and underscores our market-leader status in the body contouring category.

The TempSure Firm handpiece enhances the functionality and versatility of our already cutting-edge TempSure radiofrequency platform. The larger 60 mm handpiece allows practitioners to further expand and differentiate their practices, while treating more patients seeking to temporarily reduce the appearance of cellulite. These launches are prime examples of the continuous innovation we are committed to in order to best serve our patients and providers.”

Erik Anderson, Hologic’s Division President, Cynosure

WarmSculpting treatments with SculpSure are clinically proven, non-surgical body contouring (lipolysis) treatments designed to permanently eliminate fat cells in problem areas. The SculpSure device’s selective wavelength laser targets fat cells under the skin and raises the temperature of body fat to disrupt and destroy these cells, which are naturally eliminated over time and do not return.

The TempSure Firm handpiece is the latest innovation launched on the TempSure platform — an expandable technology that provides the ability to perform surgical and non-surgical aesthetic applications in one convenient 300W, 4MHz device. The TempSure platform is the ideal choice for practitioners across a variety of specialties with a broad range of needs, including plastic surgery, dermatology, gynecology and ophthalmology.

The new offerings from Cynosure allow practitioners to meet the growing patient demand in the expanding arena of body contouring. TempSure Firm allows me to confidently, and now more quickly, address patient needs and deliver results they’re looking for.  WarmSculpting Profile treatments with SculpSure are my go-to option for patients looking for noticeable results without surgery, and now with the expanded BMI clearance and petite mask, I can treat those who might not have been candidates before.”

Dr. Raminder Saluja, Saluja Cosmetic and Laser Center

In conjunction with these launches, Cynosure has updated its SculpSure software to include a new, optional, guided mode feature. Developed to help clinicians treat patients more easily, it features a preset algorithm for energy titration, resulting in a controlled increase in temperature to achieve lipolysis, as well as energy setting parameters designed to guide providers into a repeatable and comfortable treatment for their patients.

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Hologic, Inc.. (2019, July 29). Cynosure launches two new products to expand portfolio of aesthetic treatments. News-Medical. Retrieved on October 20, 2019 from https://www.news-medical.net/news/20190729/Cynosure-launches-two-new-products-to-expand-portfolio-of-aesthetic-treatments.aspx.

  • MLA

    Hologic, Inc.. "Cynosure launches two new products to expand portfolio of aesthetic treatments". News-Medical. 20 October 2019. <https://www.news-medical.net/news/20190729/Cynosure-launches-two-new-products-to-expand-portfolio-of-aesthetic-treatments.aspx>.

  • Chicago

    Hologic, Inc.. "Cynosure launches two new products to expand portfolio of aesthetic treatments". News-Medical. https://www.news-medical.net/news/20190729/Cynosure-launches-two-new-products-to-expand-portfolio-of-aesthetic-treatments.aspx. (accessed October 20, 2019).

  • Harvard

    Hologic, Inc.. 2019. Cynosure launches two new products to expand portfolio of aesthetic treatments. News-Medical, viewed 20 October 2019, https://www.news-medical.net/news/20190729/Cynosure-launches-two-new-products-to-expand-portfolio-of-aesthetic-treatments.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Hologic first quarter revenues increase 9.3% to $472.7 million